Introduction
Gastric cancer (GC) remains a significant global health challenge, often requiring multi-modal treatment strategies. Hyperthermia (HT), the application of heat to induce cancer cell death, has emerged as a promising adjunctive therapy. However, its clinical utility is often hampered by the "selectivity" problem: while high temperatures are effective, they risk damaging healthy tissue. Conversely, mild hyperthermia is safer but frequently triggers adaptive survival mechanisms in cancer cells, allowing them to resist thermal stress. This study identifies the long non-coding RNA (lncRNA) MALAT1 as a key regulator of this survival response through the modulation of glutamine metabolism.
The MALAT1-miR-206-GLS Regulatory Axis
The researchers investigated the molecular "shield" that protects GC cells during heat stress. They identified a signaling axis involving MALAT1, the microRNA miR-206, and glutaminase (GLS). MALAT1 functions as a competing endogenous RNA (ceRNA), acting as a molecular "sponge" that binds to and inhibits miR-206. Under normal conditions, miR-206 suppresses the expression of GLS, a critical enzyme in glutamine metabolism. By sequestering miR-206, MALAT1 effectively "releases the brakes" on GLS, fueling the metabolic pathways that support cancer cell survival.
Methods
To map this signaling pathway, the researchers utilized a multi-disciplinary approach. They analyzed 30 pairs of gastric cancer and adjacent normal tissues to establish clinical correlations. Molecular interactions were verified using luciferase reporter assays, which confirmed that MALAT1 directly sponges miR-206 and that miR-206 targets the 3’UTR of the GLS gene. Functional changes were assessed through glutamine uptake assays, GLS enzyme activity measurements, and MTT assays for cell viability. Hyperthermia was simulated by exposing cell cultures to temperatures between 37°C and 45°C for durations ranging from 30 minutes to 4 hours.
Clinical Relevance and Thermal Response
Analysis of patient tissues revealed that MALAT1 is significantly overexpressed in gastric cancer compared to adjacent normal tissues. High levels of MALAT1 and low levels of miR-206 were strongly correlated with poorer patient survival rates.
Crucially, the study found that mild hyperthermia (41–43°C) acts as a trigger for this pathway. Short-term exposure to heat induces MALAT1 expression, which in turn boosts glutamine uptake and GLS activity. This metabolic surge represents an adaptive reaction that helps the cell endure thermal stress. As shown in Figure 1, MALAT1 levels increase significantly at 41°C and 43°C, correlating with increased glutamine uptake and GLS activity.
Enhancing Hyperthermia-Induced Apoptosis
By targeting this axis, the researchers demonstrated a method to overcome heat resistance. Silencing MALAT1 or overexpressing miR-206 disrupted the metabolic "shield," significantly sensitizing GC cells to mild hyperthermia. When MALAT1 knockdown was combined with 41°C heat treatment, there was a dramatic increase in Caspase-3 activity and a corresponding decrease in cell viability, indicating a synergistic induction of apoptosis.
The "rescue" experiments were particularly definitive. When researchers manually restored GLS expression in cells where miR-206 was overexpressed, the inhibitory effects on glutamine metabolism and the increased sensitivity to heat were reversed. This confirms that the MALAT1-miR-206 axis exerts its influence primarily through the regulation of GLS-mediated glutamine metabolism.
Conclusion
The MALAT1-miR-206-GLS axis represents a critical metabolic vulnerability in gastric cancer. Targeting this pathway—either by inhibiting the lncRNA MALAT1 or boosting miR-206—offers a strategic approach to enhance the selectivity and efficacy of mild hyperthermia treatments. While further in vivo studies are necessary to validate these findings in complex biological systems, this research provides a clear molecular framework for improving outcomes in gastric cancer therapy.
Summary updated